A drug used to treat certain advanced breast cancers may offer a new treatment option for a deadly blood cancer known as myelofibrosis, new research from UVA Cancer Center suggests. The drug, palbociclib, may be able to prevent the scarring of bone marrow that existing treatments for myelofibrosis cannot.
Classifying a rare blood disorder as a cancer opened new doors for disease investigation, treatment and hope for a cure.
Blood cancers called myeloproliferative neoplasms (MPNs) are driven by mutations in a gene called JAK2. Current drugs that inhibit the protein made by mutated JAK2 don’t work as well as initially hoped. A new compound that targets this protein when it is in an inactive structural state appears to be more effective and less toxic, raising hopes that this will lead to better drugs for MPNs.
In 1951, William Dameshek described the concept of ‘myeloproliferative disorders (MPDs)’ by grouping together chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and erythroleukemia; he reasoned that a self-perpetuating trilineage myeloproliferation underlined their pathogenesis.
Suddenly, I could see my previous life – of pointless anxieties, petty rivalries and overthinking – for what it was.
Welcome to MPN Cancer Connection, where a brighter future for MPN patients shines on the horizon with opportunity, new treatments and resources for improved patient care.
Partner. Advocate. Friend. At the MPN Research Foundation, we’re committed to standing with you in the fight against polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – the group of blood cancers collectively known as myeloproliferative neoplasms.
MPN Voice offers a unique buddy system, supported by healthcare professionals, putting MPN patients in contact with other patients who can provide a sympathetic and supportive ear for when things are new, tough or confusing.
Learn about research studies for a study medication targeting Myelofibrosis.
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Jakafi is used to treat adults with certain types of myelofibrosis.
Myeloproliferative disorders – sometimes called myeloproliferative neoplasms – are cancer-like diseases in which too many blood cells are produced in the bone marrow. This hinders the normal production of blood cells. The excess blood cells can also disrupt the function of the blood.
Chronic myeloproliferative disorders are a group of slow-growing blood cancers in which the bone marrow makes too many abnormal red blood cells, white blood cells, or platelets, which accumulate in the blood.